Who is sponsoring NCT00187486?

NCT00187486 is sponsored by University of California, San Francisco.

What condition does NCT00187486 study?

NCT00187486 studies Glioblastoma Multiforme, Gliosarcoma.

What drugs are being tested in NCT00187486?

Interventions: Tarceva, Temodar, Radiation Therapy.

What is the status of NCT00187486?

NCT00187486 is currently COMPLETED.

Last reviewed 2017-08-04 · How we verify

Phase II Study of Tarceva Plus Temodar During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme and Gliosarcoma

NCT00187486 Phase 2 COMPLETED Results posted

The patients eligible for this study are those diagnosed with glioblastoma or gliosarcoma who have recently undergone surgery and who have not been treated with radiation therapy or chemotherapy. This is called a phase II study. The purpose of the phase II study is to determine how effective Tarceva plus Temodar plus radiation is in controlling the growth of glioblastoma and gliosarcoma. All patients will receive radiation and Temodar plus Tarceva. There is no "placebo" drug.

Details

Lead sponsor	University of California, San Francisco
Phase	Phase 2
Status	COMPLETED
Enrolment	66
Start date	2004-08
Completion	2011-03

Conditions

Glioblastoma Multiforme
Gliosarcoma

Interventions

Tarceva
Temodar
Radiation Therapy

Primary outcomes

Overall Survival — assessment of survival was every 2 months, up to 181 weeks
Patients were monitored until death

Countries

United States